The current financial score of Regenxbio Inc is 7.35. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 108.02M, representing a year-over-year increase of 405.73%, while its net profit experienced a year-over-year increase of 132.04%.
The current valuation score of Regenxbio Inc is 7.61. Its current P/E ratio is -1.52, which is -33.76% below the recent high of -1.01 and -202.88% above the recent low of -4.62.
The current earnings forecast score of Regenxbio Inc is 8.31. The average price target is 24.42, with a high of 50.00 and a low of 10.00.
The current price momentum score of Regenxbio Inc is 5.32. Currently, the stock price is trading between the resistance level at 11.15 and the support level at 6.84, making it suitable for range-bound swing trading.
The current institutional shareholding score of Regenxbio Inc is 7.00. The latest institutional shareholding proportion is 87.72%, representing a quarter-over-quarter increase of 3.42%.
The current risk assessment score of Regenxbio Inc is 3.02. The company's beta value is 1.05. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.